Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
作者信息
Achten Roselie, Thijs Judith, van Luijk Chantal, Knol Edward, Delemarre Eveline, de Graaf Marlies, Bakker Daphne, de Boer Joke, van Wijk Femke, de Bruin-Weller Marjolein
机构信息
Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands.
出版信息
Clin Exp Allergy. 2023 Feb;53(2):239-243. doi: 10.1111/cea.14269. Epub 2022 Dec 22.
PMID:36550628
Abstract
摘要
相似文献
1
Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.度普利尤单抗治疗的中重度特应性皮炎患者泪液中的生物标志物。
Clin Exp Allergy. 2023 Feb;53(2):239-243. doi: 10.1111/cea.14269. Epub 2022 Dec 22.
2
Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate-to-severe hidradenitis suppurativa.度普利尤单抗在重度特应性皮炎及伴发的中度至重度化脓性汗腺炎管理中的成功与安全应用。
Dermatol Ther. 2022 Aug;35(8):e15645. doi: 10.1111/dth.15645. Epub 2022 Jun 28.
3
EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.湿疹面积和严重程度指数（EASI）与改良湿疹面积和严重程度指数（p-EASI）：使用血清生物标志物组合预测接受度普利尤单抗治疗的特应性皮炎患者的疾病严重程度
Allergy. 2020 Dec;75(12):3287-3289. doi: 10.1111/all.14492. Epub 2020 Jul 24.
4
Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China.在中国，不同年龄组的中重度特应性皮炎患者接受度普利尤单抗治疗的情况。
Allergy. 2023 Jun;78(6):1696-1699. doi: 10.1111/all.15660. Epub 2023 Feb 13.
5
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial.在一项为期52周的随机对照3期试验中，度普利尤单抗可预防中度至重度特应性皮炎成人患者病情发作。
J Am Acad Dermatol. 2021 Feb;84(2):495-497. doi: 10.1016/j.jaad.2020.05.003. Epub 2020 May 7.
6
Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab.使用度普利尤单抗治疗的特应性皮炎患者出现紫癜性药疹。
Acta Derm Venereol. 2022 Jun 29;102:adv00744. doi: 10.2340/actadv.v102.2245.
7
Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study).探索生物标志物以预测接受度普利尤单抗治疗的特应性皮炎患者的临床改善情况（B-PAD研究）。
Clin Exp Allergy. 2023 Feb;53(2):233-238. doi: 10.1111/cea.14267. Epub 2022 Dec 16.
8
Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab.特应性皮炎控制工具在接受度普利尤单抗治疗的中重度特应性皮炎患者长期监测中的新作用
Dermatitis. 2024 Jan-Feb;35(S1):S107-S108. doi: 10.1089/derm.2023.0052. Epub 2023 Aug 18.
9
An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab.一项关于从度普利尤单抗转换治疗后使用阿布昔替尼治疗中度至重度特应性皮炎成人患者的观察性研究。
J Am Acad Dermatol. 2023 Oct;89(4):826-828. doi: 10.1016/j.jaad.2023.05.077. Epub 2023 Jun 10.
10
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
Zotero 插件